Briefing Summary: US FDA Posts Advisory Committee Materials for Discussion About How to Communicate the Fetal Effects of Methadone or Buprenorphine for Opioid Addiction – JUN 8-9, 2015 (RCAC)
The US FDA has posted details, including FDA Briefing Materials, for the Monday and Tuesday, June 8-9, 2015 Risk Communications Advisory Committee (RCAC). The Committee will discuss approaches to communicating information about fetal effects in product labeling for methadone or buprenorphine maintenance therapy for opioid addiction, and about the maternal benefits and risks of treatment, to best enable patients and healthcare providers to make informed decisions about the use of these drugs during pregnancy.